Shenzhen Hepalink Pharmaceutical Group Co Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges – IT Business Net

Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesDonald mccaffreyNewsfile corpResverlogix corpToronto stock exchangeShenzhen hepalink pharmaceutical group co ltdToronto stockLooking statementsAnnual information form

Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesDonald mccaffreyAlberta newsfile corpShenzhen hepalink pharmaceutical group co ltdToronto stock exchangeResverlogix corpToronto stockLooking statementsAnnual information form

Resverlogix Corp : Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Resverlogix Corp : Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesDonald mccaffreyAlberta newsfile corpResverlogix corpToronto stock exchangeShenzhen hepalink pharmaceutical group co ltdToronto stockLooking statementsAnnual information formChance des

Shenzhen Hepalink Pharmaceutical Group (OTCMKTS:SHEZF) Cut to Sell at The Goldman Sachs Group

The Goldman Sachs Group lowered shares of Shenzhen Hepalink Pharmaceutical Group (OTCMKTS:SHEZF – Free Report) from a neutral rating to a sell rating in a research report sent to investors on Thursday morning, FlyOnTheWall reports. Shenzhen Hepalink Pharmaceutical Group Stock Performance SHEZF opened at $0.72 on Thursday. Shenzhen Hepalink Pharmaceutical Group has a twelve month […]

United statesHong kongManufacturing organizationShenzhen hepalink pharmaceutical group co ltdGoldman sachs groupShenzhen hepalink pharmaceutical group company profileContract developmentShenzhen hepalink pharmaceutical groupShenzhen hepalink pharmaceutical group stock performanceFree reportGet free reportMainland chinaActive pharmaceutical ingredientsShenzhen hepalink pharmaceutical group dailyOtcmkts shezfThe goldman sachs group inc

Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K -Today at 05:16 pm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT .

United statesLos gatosVu truongShenzhen hepalink pharmaceutical group co ltdSecurities exchangeAridis pharmaceuticals incShenzhen arimab biopharmaceuticals co ltdExchange actSecurities actSecurities exchange actMaterial definitiveAridis pharmaceuticalsRestated technology licenseCollaboration agreement